delta

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

Click arrow to play
Download TWiV 914 (22MB .mp3, 37 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Show notes at microbe.tv/twiv

In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana. 

Click arrow to play
Download TWiV 905 (29 MB .mp3, 48 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.

Click arrow to play
Download TWiV 901 (36 MB .mp3, 60 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.

Click arrow to play
Download TWiV 895 (33 MB .mp3, 54 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv